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Abstract
Epidermal growth factor-like domain 7, Egfl7, is a largely endothelial restricted gene which is thought to have a
role during the differentiation of embryonic stem cells (ESCs) along the endothelial lineage. While it has been
shown that Egfl7 knock-down in zebrafish impairs endothelial cord formation, the role of the gene in mammals has
been unresolved. Interpretation of mouse knockout studies has been complicated by the fact that deletion of miR-
126, an intronic microRNA located within Egfl7, results in vascular defects. Here we use an siRNA knock-down
approach to target specific regions of Egfl7 without affecting miR-126 expression. Egfl7 was knocked down in
mouse ESCs and the effect on vascular development was assessed using the in vitro embryoid body (EB) model
after either 7 or 14 days of differentiation. Knock-down of Egfl7 resulted in the formation of abnormal sheet-like
CD31+ structures that were abundant within EBs after 7 days of differentiation. Only up to 60% of these sheets co-
expressed basement membrane and endothelial cell junction markers. Similar CD31+ sheets were also seen as out-
growths from 7 day EBs into collagen gels. A partial remodelling occurred by 14 days of differentiation when fewer
CD31+ sheets were seen both within EBs, and as outgrowths from EBs. Formation of these sheets was due, at least
in part, to increased proliferation specifically of CD31+ cells. Cell death within EBs was unaffected by Egfl7 knock-
down. In conclusion, our work shows that knock-down of Egfl7 causes defects in early vascular cord formation, and
results in the development of CD31+ sheet-like structures. This suggests that Egfl7 is vital for the formation of
endothelial cell cords, and that the gene has an important role during both vasculogenesis and angiogenesis in
mammalian cells.
Background
Epidermal growth factor-like domain 7, Egfl7, was iden-
tified in a screen for genes with restricted expression
during in vitro differentiation and mouse embryogenesis
[1]. EGFL7 is expressed in undifferentiated mouse
embryonic stem cells (ESCs), during early embryogen-
esis at sites of blood island formation and vasculogen-
esis, and in adults during pathological and physiological
angiogenesis [1,2] (L. Campagnolo and H. Stuhlmann,
Unpublished). Expression of EGFL7 is largely restricted
to endothelial cells (ECs), and is down-regulated in
most adult organs with the exception of the pregnant
uterus and during wound repair [1,2]. In addition,
expression has also been reported in primordial germ
cells and male germ cells [3]. Due to its early and
restricted expression, Egfl7 has been proposed to have a
role during the differentiation of ESCs along the
endothelial lineage. EGFL7 is a secreted protein which
stimulates EC migration, and knock-down of the gene
in zebrafish results in a severe impairment of arterial
and venous EC cord segregation leading to the forma-
tion of midline angioblast aggregates [2,4,5]. However,
the function of Egfl7 in mammalian vascular develop-
ment is still unresolved. In a mouse knockout study,
Schmidt et al [6] showed partial embryonic lethality,
delayed vascular development, and abnormal EC aggre-
gates. In contrast, Kuhnert et al [7] found no phenotype
in Egfl7 knockout mice, and instead proposed that the
observed vascular defects could be attributed to deletion
of miR-126, an endothelial microRNA located within
intron 7 of Egfl7. In this study we have used an siRNA
knock-down approach, enabling us to target regions of
the Egfl7 gene other than intron 7. This has allowed us
to specifically investigate the role of Egfl7 during vascu-
lar development, without affecting miR-126 expression.
We chose the embryoid body (EB) differentiation
model to examine the effect of Egfl7 knock-down on
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dies have shown that EBs facilitate the interaction of
cells of the ectodermal, mesodermal, and endodermal
lineages, recapitulating the developmental kinetics of
normal mouse embryonic development [8-11]. Because
EBs are initially formed by differentiating ESCs, this sys-
tem allows for assessment of vascular structure develop-
ment and the process of ESC differentiation to be
assessed. Recent work has shown that vascular struc-
tures within EBs are surrounded by a basement mem-
brane, as is the case for blood vessels in vivo [12]. We
used EBs that were differentiated for 7 days, roughly
equivalent to an early organogenesis stage, and 14 days,
which is considered to be a later remodeling stage [13].
We also looked at the effect of Egfl7 knock-down on
sprouting angiogenesis using EBs in a type I collagen
gel. Here we show that Egfl7 knock-down results in the
formation of abnormal endothelial sheet-like structures,
which form during the initial stages of in vitro vascular
development. During the subsequent processes of differ-
entiation, presumably involving remodelling, endothelial
cords replace a large proportion of these sheets. Our
results suggest a role for Egfl7 in EC organization, and
indicate that the gene is necessary for normal vascular
growth during both vasculogenesis and angiogenesis in
mammalian cells.
Methods
Knock-down construct and siRNA production
The siRNA sequences used for Egfl7 knock-down (KD1,
KD2, KD3), and the scrambled controls (Scr1, Scr2)
were as follows; KD1: 5’-UACUUGCCAGACAGAU-
GUU-3’ (sense), 3’-UUAUGAACGGUCUGUCUAC-5’
(antisense); KD2: 5’-GCAGCUGGACCGAAUUGAU-3’
(sense), 3’-UUCGUCGACCUGGCUUAAC-5’ (anti-
s e n s e ) ;K D 3 :5 ’-GCUCCCUGUCUAAGUGGUAA-3’
(sense), 3’-UUCGAGGGACAGAUUCACCA-5’ (anti-
sense); Scr1: 5’-GCUCCCUAGGCUAGUGGUAA-3’
(sense), 3’-UUCGAGGGAUCCGAUCACCA-3’ (anti-
sense); Scr2: 5’-UACUUGGACGACAGAUGUU-3’
(sense), 3’-UUAUGAACCUGCUGUCUAC-5’ (anti-
sense). Sense and antisense oligonucleotides were
annealed and ligated to linearised psiRNA-hH1neoG2
vector (Invitrogen) before sub-cloning into the FG12 len-
tiviral vector carrying an eGFP reporter sequence [14].
Production of lentivirus and stable embryonic stem cell
knock-down clones
HEK 293T cells were co-transfected with FG12 lentiviral
vectors carrying the siRNA sequence, HIV-1 lentiviral
packaging constructs (pMDLg/pRRE and pRSV-REV),
and pVSV-G (a plasmid coding for the G protein of the
vesicular stomatitis virus) by the calcium phosphate
method. Virus supernatant was collected 24-40 h after
transfection and concentrated by ultracentrifugation
(22,000 × g). The virus titers were determined on 3T3
cells by counting the number of eGFP+ cells under a
microscope, and were 5 × 10
6-1.5 × 10
8 infectious units/
ml. Mouse ESCs (W4/129S6; Taconic) were grown on a
feeder layer of irradiated mouse embryonic fibroblasts
(MEFs) in DMEM supplemented with 15% FBS, 20 mM
HEPES, 0.1 mM non-essential amino acids, 0.1 mM b-
mercaptoethanol, 100 U/ml penicillin/streptomycin, 0.3
mg/ml L-glutamine, and 10
3U/ml LIF (ESGRO; Chemi-
con). ESCs were infected in the presence of 8 μg/ml
polybrene at a MOI of 1-2. Individual eGFP+ clones
were isolated and assessed for expression of the knock-
down construct by RT-PCR and western blot. RNA and
protein was extracted from cells using the PARIS kit
(Ambion) as per manufacturer’s instructions. Reverse
transcription was carried out using the SuperScript III
First-Strand Synthesis System (Invitrogen), followed by
PCR using the following primers; Egfl7:5 ’-ACAGACC-
CAGCCGTAGAGTG-3’ (forward, spanning exons 3 and
4), 5’-TCAATTCGGTCCAGCTGCTGG-3’ (reverse,
within exon 9); GAPDH:5 ’-ACCACAGTCCATGCCAT-
CAC-3’ (forward), 5’-TCCACCACCCTGTTGCTGTA-3’
(reverse). For westerns, 40 μgp r o t e i nw a sr u no na1 0 %
bis-tris gel (Invitrogen) under reducing conditions, and
transferred to a PVDF membrane which was incubated
with antibodies against EGFL7 [1] and actin (Santa
Cruz), followed by HRP-conjugated secondary antibo-
dies. Images of eGFP+ ESCs were taken with a Leica
DFC340FX digital colour camera mounted on a Leica
DMIL inverted microscope, using Leica Application
S u i t eS o f t w a r e( L e i c aM i c r o s y s t e m s ) ,a n de G F P +E B s
were visualized using a stereo Discovery. V20 micro-
scope (Carl Zeiss) with an X-Cite 120 external fluores-
cent light source (EXFO Photonic Solutions Inc.)
Real-time PCR analysis of Egfl7 and miR-126 levels
For real-time PCR analysis, total RNA was isolated from
ESCs using the RNAqueous-Micro Kit (Ambion) as per
manufacturer’si n s t r u c t i o n s .Egfl7 levels were deter-
mined by carrying out reverse transcription as described
above, followed by PCR using the following primers;
Egfl7 (spanning intron 8) 5’-AGAGGAGGTGTA-
CAGGCTGCA-3’ (forward), 5’-TTCGGTCCAGC
TGCTGGAAGGAAT-3’ (reverse); b-actin:5 ’-CCAT
CATGAAGTGTGACGTTG-3’ (forward), 5’-CAAT
GATCTTGATCTTCATGGTG-3’ (reverse). Levels of
the microRNAs miR-126-3p and miR-126-5p were deter-
mined by first carrying out reverse transcription using
microRNA-specific primers and the Taqman MicroRNA
Reverse Transcription Kit (Applied Biosystems). PCR
was then done using Taqman MicroRNA Assay
(Applied Biosystems), and levels of expression were nor-
malized to miR-16.
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ESC growth rates were determined essentially as
described by Udy et al [15]. ESCs were plated on MEFs
in 12 well plates at 30 cells/well. At each time point
(4-8 days after plating) ESCs from triplicate wells were
trypsinized, MEF-depleted, and counted using a haemo-
cytometer. Averages of triplicate counts were compared
by two-way ANOVA with repeated measures and
a Bonferroni post-test using Prism4 (GraphPad
Software, Inc.).
Embryonic stem cell differentiation as embryoid bodies
ESCs were MEF-depleted and seeded in 30 μlh a n g i n g
drops at 8 × 10
4 cells/ml in differentiation medium (as
for ES cell media, except 20% FBS and no LIF). Two
days later EBs were grown in suspension, and then har-
vested at either 7 or 14 days after initial seeding. Where
TGF-b was used, 2.5 ng/ml recombinant human TGF-b
(R&D Systems) was added to medium prior to making
hanging drops, and also for subsequent feeding. In other
experiments, conditioned medium from wild-type, or
scrambled control, EBs was used on knock-down clones
during differentiation to day 7 EBs. EBs were fixed in
4% PFA followed by 10% and 20% sucrose, and frozen
in a 1:1 solution of OCT: 30% sucrose. 12 μm sections
were used for indirect immunofluorescence (IF) staining.
Collagen type I sprouting angiogenesis assay
Ten individual 7 or 14 day EBs were plated onto 1.5 ml
of solidified collagen type I medium in a 35 mm dia-
meter plate and allowed to settle overnight in differen-
tiation medium, before a second collagen layer was
added. The collagen medium was made as described by
Feraud et al [16] with a final concentration of rat tail
type I collagen of 1.25 mg/ml (BD Biosciences). Recom-
binant growth factors were used at final concentrations
known to provide maximal biological stimulation:
human VEGF165, 50 ng/ml; mouse FGF basic, 100 ng/
ml; mouse Epo, 20 ng/ml; human IL-6, 10 ng/ml (R&D
Systems) [17]. After nine days the gels were quickly
dehydrated on glass slides using nylon linen and filter
paper, and air-dried overnight before being stored at
-80°C until staining.
Indirect immunofluorescence staining
EB cryosections were fixed in ice-cold acetone, or
methanol (for Flk1 staining), and EBs within collagen
type I gels were fixed in 4% PFA. Samples were
blocked with 10% normal donkey serum and 5% non-
fat dried milk, and antibodies were diluted in 5% non-
fat dried milk. Collagen gels were also permeabilized
using 0.5% triton X-100. For Annexin-V staining 2%
BSA was used instead of milk. Sequential double-stain-
ing was carried out with the anti-CD31 antibody first,
and antibodies were used as follows; rat anti-mouse
CD31, 5 μg/ml (BD Biosciences), goat anti-mouse
Flk1, 4 μg/ml (Santa Cruz), rabbit anti-mouse Collagen
IV, 5 μg/ml (Chemicon), goat anti-mouse VE-Cadherin,
5 μg/ml (R&D Systems), rabbit anti-mouse Claudin-5, 2.5
μg/ml (Invitrogen), rabbit anti-mouse Ki67, 1.5 μg/ml
(Abcam), rabbit anti-mouse Annexin-V, 2.5 μg/ml
(Abcam). Rat, rabbit, and goat IgG controls were used
on adjacent sections. Signals were detected with donkey
anti-rat IgG conjugated with Cy3 or Cy5, and donkey
anti-rabbit or -goat IgG conjugated with Cy5 or Cy3
(Jackson ImmunoResearch). Cryosections were mounted
in ProLong Gold Antifade reagent with DAPI (Invitro-
gen). Collagen gels were incubated with Hoechst 33342
nuclear dye (Invitrogen) and mounted in Vectashield
hard-set mounting medium (Vector Labs). Images were
taken using an Axioplan 2 imaging microscope (Carl
Zeiss), or a Leica TSC SP2 confocal laser microscope
(Leica Microsystems).
Quantification of vascular structures
For quantification of EB cryosections and collagen gel-
embedded EBs, image acquisition was performed with
an ORCA-ER black and white camera (Hamamatsu
Photonics) driven by Openlab software (Improvision,
Ltd.). Relative CD31+, Ki67+, and DAPI+, areas were
measured by determining the number of pixels corre-
sponding to the fluorescent signal using the ‘magic
wand tool’ in Photoshop (Adobe Systems Inc.). Indivi-
dual EBs were also scored for the presence of CD31+
‘cords’, ‘sheets’, or both. Cords were defined as CD31+
structures of more than two cells in length, and not
more than two cells in width, determined by counting
DAPI-stained nuclei in overlaid images. CD31+ sheet
structures were defined as being more than four cells in
diameter, and more than four cell’sd i s t a n c ef r o m
another sheet to be counted individually. CD31+ sheets
were also analyzed separately, and the Ki67+ pixels
within each sheet determined. Where indicated, confocal
images were captured using Leica Confocal Software. All
analysis for the collagen gel-embedded EBs was done
using Photoshop. Relative CD31+ sprout length was
determined using the ‘measure’ tool and branching
points were defined as where two or more CD31+
sprouts radiated from. All statistical analysis was carried
out using Prism4 (GraphPad Software, Inc.).
Results and Discussion
Lentiviral-mediated knock-down of Egfl7
The FG12 lentiviral vector [14,18] was used for delivery
of siRNAs into ESCs. This vector has an RNA polymer-
ase III promoter (H1) to drive siRNA expression, and an
UbiC promoter to drive marker gene (eGFP) expression
(Figure 1a). The use of RNA polymerase III and UbiC
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mediated knock-down [14,19]. The eGFP expression
serves as a reliable marker to demonstrate the presence
and expression of the Egfl7 siRNA knock-down
sequence. The siRNA constructs were designed to
knock-down Egfl7 by targeting different regions of the
Egfl7 gene; spanning coding exons 6 and 7 (KD1), within
exon 9 (KD2), and in the 3-prime untranslated region in
exon 10 (KD3) (Figure 1a). These constructs reduced
Egfl7 expression at the RNA level by 75-95%, and also
significantly reduced expression at the protein level
(Figure 1b). Reporter eGFP expression was visible in sta-
bly infected ES cells, and for at least 14 days after differ-
entiation in vitro (Figure 1c). Three control constructs
were also used; one being the lentiviral vector with no
siRNA sequence (Empty), and two containing scrambled
sequences (Scr1, Scr2). ESCs were infected at an MOI
of 1-2 providing a single or low proviral copy number
per cell. Throughout all experiments results were con-
sistent between the knock-down constructs, and
between the empty and scrambled controls. Importantly,
quantitative PCR showed that Egfl7 knock-down did not
affect levels of the microRNAs miR-126-3p (3 prime
end) or miR-126-5p (5 prime end) (Figure 1d), which
are generated as a stem loop encoded by intron 7 within
the Egfl7 g e n e( F i g u r e1 a ) .W ew e r et h e r e f o r ea b l et o
study the specific effect of Egfl7 knock-down, without
any possible effects on altered miR-126 levels. Because
Egfl7 expression is restricted to undifferentiated ES cells,
early mesodermal precursors of vascular endothelial
cells, and to the vasculature during development [1],
lentiviral infection of ESCs will only affect the corre-
sponding cell types in the differentiating EBs that nor-
mally express Egfl7.
Egfl7 knock-down reduces embryonic stem cell growth
rate
To determine whether Egfl7 knock-down affected undif-
ferentiated ESC proliferation rate, cell counts were
recorded between days 4 and 8 after plating at low den-
sity. Knockdown was associated with a significantly
reduced growth rate compared with those infected with
empty lentivirus and scrambled controls (Figure 2).
Egfl7 is expressed at the RNA and protein level in
undifferentiated ESCs [1], (L. Campagnolo and H.
Stuhlmann, Unpublished data), and therefore this result
suggests that Egfl7 has a role in ESC proliferation or
self-renewal.
Abnormal endothelial sheets form in Egfl7 knock-down
embryoid bodies
EBs were formed from the three knock-down and three
control ESC clones by the hanging drop method [20]. In
vitro differentiation occurred at similar rates for all
clones, with no differences observed in the size or num-
ber of EBs (data not shown). During in vitro differentia-
tion EBs grow from simple aggregates of ES cells at 2-4
days, to being cystic EBs which resemble the visceral
yolk sac of post-implantation embryos after 8-10 days
[8,13]. In the present work this progression was
observed between the earlier (7 day) and later (14 day)
time points, and cysts/cavities can clearly be seen in
cryosections of day 14 EBs (e.g. Figures 3c and 3d). Nor-
mal developmental processes account for the formation
of cavities, as well as complex networks of cords, within
the day 14 EBs. Furthermore, Annexin V staining did
not indicate abnormally high levels of apoptosis/necrosis
in the day 14 EBs, thus indicating that there was no
increased degradation associated with cavitation (see
below).
Vascular structures within EBs were analyzed at 7 days
and 14 days of differentiation, as these time points cor-
respond approximately with early organogenesis and
later remodelling stages respectively [13]. Sections
through EBs revealed the presence of two clearly distin-
guishable CD31+ cell structures, which we describe here
as ‘cords’ (Figure 3; arrows) and ‘sheets’ (Figure 3;
arrowheads). ‘Cords’ are defined as more than two
CD31+ cells in length and a maximum of two CD31+
cells in width, and ‘sheets’ as aggregates of more than
four CD31+ cells in length and width. These structures
were viewed on 2-dimensional cryosections through
EBs. Due to the spherical shape of EBs it is probable
that the ‘cords’ are part of a larger network existing in
multiple axes within the EBs, and that the ‘sheets’ repre-
sent one plane within 3-dimensional clusters of CD31+
cells. Similar CD31+ ‘sheets’ have been described in EBs
d e r i v e df r o ml a m i n i ng1-deficient ESCs [12]. To further
characterize the CD31+ structures present, EB sections
were co-stained with antibodies against other endothe-
lial markers. Collagen IV is a major constituent of the
basement membrane, and its deposition is characteristic
of normal blood vessel formation and is required for
subsequent angiogenesis [12,21,22]. Vascular endothelial
(VE)-cadherin is the major transmembrane component
of adherens junctions, and sustains cell-cell recognition
and adhesion [23]. Used together with CD31, which is
expressed on haematopoietic cells as well as ECs,
VE-cadherin is considered to be the gold standard for
EC-specific markers [24]. Claudin-5 is an endothelial-
specific component of tight-junctions, which control
para-cellular permeability and polarity [25,26]. Flk1, a
VEGF-A receptor, is an early marker of hematopoietic
and endothelial cells [27].
At the day 7 time point CD31+ cords which co-
expressed collagen IV, VE-cadherin, and claudin 5 were
seen in all of the control and knock-down clones
( F i g u r e s3 a ,f ,g ,k ,a n d3 l ;a r r o w s ) .H o w e v e r ,t h e
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Page 4 of 12Figure 1 Knock-down of Egfl7 expression in mouse embryonic stem cells.( a) Lentiviral construct used for siRNA-mediated knock-down of
Egfl7 (top), and Egfl7 gene structure (bottom) showing non-coding (unshaded) and coding (shaded) exons. The three siRNA target sequences
are shown as red bars, and the location of the microRNA miR-126 is shown within intron 7. (LTR, long terminal repeat; Flap, DNA flap; H1, human
H1 RNA pol III promoter; UbiC, human ubiquitin c promoter; eGFP, enhanced green fluorescent protein; WRE, woodchuck response element). (b)
Verification of Egfl7 knock-down in mouse ESCs by RT-PCR (top) and western blot (bottom). (Empty, lentiviral construct alone; 1, 2, 3
(corresponding to KD1, KD2, KD3), lentivirus containing siRNA sequence; scrambled, lentivirus containing scrambled siRNA control sequence; +,
HEK293 cells transfected with a His-tagged Egfl7 vector). (c) Endogenous eGFP expression in lentivirus infected undifferentiated ESCs 8 hours
after plating (left two panels) and after passaging 5 times (middle two panels), and in ESC-derived EBs after 14 days of differentiation (right two
panels). Magnification used 69×. (d) Quantitative PCR was carried out for Egfl7 and the microRNAs miR-126-3p and miR-126-5p. Expression was
normalized to b-actin (for Egfl7)o rmiR-16 (for the microRNAs), and is shown relative to a value of 1.0 for the scrambled control 2 (Scr2).
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tinguished the knock-down clones from the controls
( F i g u r e s3 b ,g ,l ,a n d3 q ;a r r o w h e a d s ) .B yd a y1 4o fd i f -
ferentiation more extensive endothelial cord networks
h a df o r m e di na l lo ft h ec l o n e s( F i g u r e s3 c ,d ,h ,i
( i n s e t ) ,3 m ,n ,r ,a n d3 s ;a r r o w s ) ,a n ds o m es h e e t sw e r e
still present in the knock-down EBs (Figures 3d (inset),
3i, and 3s). Quantification of the CD31+ structures
revealed a striking difference between controls and
knock-downs. At day 7 the majority of the control EBs
contained cords, whereas most of the knock-downs con-
tained sheets as well as cords (Figure 4a). The spatial
organization of ECs within these sheets were reminis-
cent of the midline angioblast aggregates seen in Egfl7
knockdown zebrafish, as well as the sheet-like endothe-
lial projections seen in aortic ring assays using Egfl7
knock-out mice [4,6]. In the EB model CD31+ sheets
were seen at the early organogenesis stage and less so at
the later remodelling time point, suggesting a role for
Egfl7 specifically at early stages of cord-formation, and
subsequent remodelling of some of these structures.
The percentage of CD31+ sheets in the knock-down
clones which co-expressed other endothelial proteins fell
from 15% (collagen IV), 58% (VE-cadherin), and 60%
(claudin 5) at day 7, to 7% (collagen IV), 31% (VE-cad-
herin), and 43% (claudin 5) at day 14. Furthermore, Flk1
did not co-localize with the CD31+ sheets (Figures 3q
and 3s). Because expression of Egfl7 during ESC differ-
entiation precedes that of Flk1 [1], Egfl7 knock-down
may affect very early stage endothelial progenitor cells,
suggesting that the CD31+ sheets are unlikely to contain
immature endothelial cells. Together, these data indicate
that the CD31+ sheets are aggregates of abnormal, vas-
cular endothelial structures, which do not lay down an
extensive basement membrane, or form normal cell-cell
junctions. To determine whether knock-down of Egfl7
affected the size of CD31+ areas within EB sections,
pixel numbers were compared between clones. Using
Photoshop software (Adobe Systems Inc.) the number of
CD31+ pixels on images of EB sections was normalized
Figure 2 Effect of Egfl7 knock-down on embryonic stem cell growth rate. Knock-down of Egfl7 resulted in a reduced growth rate in
undifferentiated mouse ESCs. The experiment was carried out three times, yielding similar results. (* p < 0.05, ** p < 0.01, †† p < 0.001; Emp,
empty lentiviral construct; Scr1, Scr2, Scrambled siRNA sequences; KD1, KD2, KD3, Knock-down siRNA sequences).
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in EB size. Egfl7 knock-down clones had a larger relative
CD31+ area compared with controls at both the 7 and
14 day time points (Figure 4b), which is most likely to
be due to the presence of sheets in the knock-down
EBs. At the 14 day time point the number of sheets
within the knock-down clones was decreased (Figure
4a), suggesting that the more extensive cord networks
accounted for the larger CD31+ area, compared with
the controls. At the early time point CD31+ sheets were
far less prevalent in control EBs than in Egfl7 knock-
down clones, indicating that these structures are not
part of a normal vascular development process. Knock-
down of Egfl7 resulted in fewer EBs containing CD31+
cords only, and a higher percentage containing both
cords and sheets (Figure 4a). It is possible that at the
later time point sprouts may form from cells contained
within sheets, or that sheets form at the expense of, or
in addition to, cords. However, it is most likely that
sheets form in addition to cords, since few EBs contain
sheets only.
When conditioned medium from wild-type, or
scrambled control, EBs was added to cultures of knock-
down ESCs during differentiation to day 7 EBs, we did
not observe a rescue of the mutant phenotype (data not
shown). This suggests that Egfl7 may act in a cell-auton-
omous manner. It has recently been shown that inhibi-
tion of the anti-proliferative transforming growth factor
beta (TGF-b)d u r i n gin vitro differentiation of human
ESCs results in a 36-fold increase in the number of
committed ECs generated [28]. Therefore, to address
whether EGFL7 and TGF-b might interact, EBs were
grown in the presence of TGF-b, which resulted in no
significant decrease in CD31+ area in knock-down EBs,
whereas control EBs showed a more robust decrease
(Figure 4c). Thus, if TGF-b is involved in the function
of Egfl7, it is unlikely to have a major role in maintain-
ing the CD31+ cell population.
Figure 3 Effect of Egfl7 knock-down on in vitro endothelial development. Cryosections of EBs at day 7 (a, b, f, g, k, l, p, q) and day 14 (c, d,
h, i, m, n, r, s) were subjected to indirect IF using antibodies against CD31 plus collagen IV (a-d), CD31 plus VE-cadherin (f-i), CD31 plus claudin 5
(k-n), or CD31 plus Flk1 (p-s). Magnification used; (a-d, f-i, k-n) inserts show whole EBs at 20×, and large panels show detail at 63×, (p-s) panels
show EBs at 20×, (e, j, o, t) panels show whole EB IgG controls at 20× (arrows, CD31+ cords; arrowheads, CD31+ sheets). Images were acquired
using a confocal laser microscope (Leica Microsystems; a-o) or an Axioplan 2 imaging microscope (Carl Zeiss; p-t).
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To address whether over-proliferation or reduced apop-
tosis of CD31+ cells contributed to the formation of the
abnormal aggregates in knock-down clones, EB sections
were co-stained with antibodies against Ki67 and
Annexin V. The nuclear protein Ki67 is a marker for
proliferation, and Annexin V is visible only in apoptotic
and necrotic cells [29,30]. At the 7 day time point there
were many Ki67+ cells in the control EBs, whereas the
knock-downs contained fewer of these cells, indicating
reduced proliferation compared with the controls
(Figures 5a and 5b; Figure 6a). At the 14 day time point
all of the EBs, regardless of genotype, contained fewer
Ki67+ cells compared with the 7 day EBs (Figures 5c
and 5d; Figure 6a). In contrast, the number of cells
expressing Annexin V increased over time, but did not
differ between the controls and knock-downs (Figures
5f, g, h, and 5i). Despite a significant reduction in prolif-
eration compared with controls (Figure 6a), all of the
day 7 knock-down clones showed at least equal, if not
higher, levels of proliferation within CD31+ sheets com-
pared with the whole EB area (Figure 6b). This suggests
that while knock-down of Egfl7 resulted in reduced pro-
liferation, the abnormal CD31+ sheet areas proliferated
as much as, if not more than, the rest of the EB struc-
ture. Since Egfl7 knock-down did not affect Annexin V
levels (Figures 5f, g, h, i, and 5j), this suggests that the
CD31+ sheets were not the result of localized cell death.
It is therefore likely that these sheets occur, at least in
part, due to over-proliferation of CD31+ cells in the
knock-down clones. At the later time point the number
of CD31+ sheets was markedly reduced, and those that
Figure 4 Quantification of CD31+ structures within embryoid bodies. (a) Percentage of EBs containing CD31+ cords only, sheets only, both
cords and sheets, or neither structure, as defined in Methods. (b) Relative CD31+ area on EB sections, measured in pixels and shown as a ratio
of DAPI+ pixel number. Statistical significance was determined by one-way ANOVA followed by a Bonferroni post-test. (c) Relative CD31+ area
on EBs sections; EBs grown +/- TGF-b. Statistical significance was determined by two-tailed, unpaired, t-tests. Bars are means ± S.E.M. (Emp,
empty lentiviral construct; Scr1, scrambled siRNA sequence; KD1-3, knock-down siRNA sequences; n = 16-36 for controls, n = 20-29 for knock-
downs; * p < 0.05, ** p < 0.01, † p < 0.005, †† p < 0.001). The data shows results from one experiment, which was carried out twice with similar
results.
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tive cells than in the entire EB. Since knock-down of
Egfl7 reduced both the proliferation of undifferentiated
ESCs (Figure 2) and the overall proliferation in day 7
EBs (Figure 6a), CD31+ sheets are unlikely to be the
result of a general increase in numbers of ESCs or cells
within EBs.
Egfl7 knock-down is associated with endothelial sheet
formation during sprouting angiogenesis
We next examined the effect of Egfl7 knock-down on
sprouting angiogenesis by seeding day 7 and day 14 EBs
between layers of type I collagen and maintaining them
for 11 days, a method which has been shown to recapi-
tulate the early stages of angiogenesis [31]. Type I col-
lagen is the major peri-capillary connective tissue
protein and interacts with EC surface proteins during
vessel sprouting and network formation [32], thus pro-
viding a physiologically relevant milieu for angiogenesis
assays. EBs were differentiated as before for 7 or 14
days, and then placed between two layers of collagen gel
in the presence of growth factors known to stimulate
angiogenesis [17]. All EBs grew CD31+ sprouts (Figures
7 a ,b ,d ,a n d7 e ;a r r o w s )h o w e v e rEgfl7 knock-down
clones also grew sheets of CD31+ cells (Figure 7b;
arrowheads). Quantification of the CD31+ outgrowths
from 7 day EBs showed that a higher percentage of
knock-down clones contained sprouts compared with
the controls, and that only knock-down clones showed
sheet formation (Figure 8a). EBs placed in the collagen
gel after 14 days of differentiation showed no differences
in the number of EBs with sprouts or sheets (Figure 8b).
Compared with the controls, day 7 knock-down EBs
showed a 35-83% increase in relative sprout length,
however this was not statistically significant due to high
variation between EBs (Figure 8c). Day 14 knock-down
EBs did not show consistent differences in CD31+
sprout length compared with the controls (Figure 8d).
Control and knock-down EBs showed no differences in
the number of sprouts per EB or the number of branch
points, at either time point (data not shown). It is inter-
esting to note that in the Egfl7 knock-down clones more
CD31+ sheets grew from the EBs that had been differ-
entiated for 7 days rather than 14 days, prior to placing
in collagen. Egfl7 knockdown EBs differentiated for
7 days presumably contained CD31+ sheets prior to the
sprouting assay (Figure 4). This suggests that early
defects caused by knock-down of Egfl7 during develop-
ment also affected EC sprouting during subsequent
angiogenesis. Together, these results indicate that
Egfl7 may be involved in sprouting angiogenesis, as
knock-down of the gene resulted in a trend towards
longer sprouts, as well as formation of sheets of
CD31+ cells.
Recent work by Kuhnert et al [7] suggests that Egfl7-
null mice are phenotypically normal, and that deletion
of miR-126 causes embryonic lethality, edema, and
hemorrhage, and postnatal defects in retinal and cranial
angiogenesis. Thus, a possible role of Egfl7 in mammals
has so far been elusive. Our studies are the first to show
a clear role for Egfl7 in the formation of vascular struc-
tures in the EB in vitro differentiation model. In sup-
port, recent studies in transgenic mice show that Egfl7
overexpression results in hemorrhaging and defects in
Figure 5 Effect of Egfl7 knock-down on embryoid body proliferation and apoptosis. Cryosections of EBs differentiated for 7 or 14 days
were subjected to indirect IF using antibodies against CD31 plus Ki67 (40× magnification used; upper panels, a-d), or CD31 plus Annexin V (20×
magnification used; bottom panels, f-i), (arrow, CD31+ cord; arrowhead, CD31+ sheet; asterisks, Annexin V+ cells). IgG controls are shown at 40×
and 20× magnification (e, j). Images were acquired using an Axioplan 2 imaging microscope (Carl Zeiss).
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H. Stuhlmann, Unpublished). The apparent discrepancy
between studies using mouse knockout models, and the
present work, could be explained by the fact that the
Egfl7 phenotype detected in EBs is subtle, early, and
transient. A strength of using the EB model system is
the possibility to detect a transient and rather subtle
phenotype in Egfl7 knock-down clones, which is evident
at day 7 of differentiation, and then partially remodeled
by day 14.
In conclusion, our results suggest that Egfl7 is vital for
the organization of ECs into vascular cords and confirm
that the gene has an important role during vasculogen-
esis and angiogenesis. We have shown that knock-down
of Egfl7 results in the formation of CD31+ sheets, and
our data support the notion that this is caused at least
Figure 6 Quantification of Ki67+ cells within embryoid bodies. The effect of Egfl7 knock-down on in vitro proliferation was quantified in day
7 and day 14 EBs using an antibody against Ki67. Relative Ki67+ area was measured in pixels and shown as a ratio of DAPI+ pixel number. (a)
Whole EB sections were compared between control and knock-down clones at each time point (n = 10-16 for controls, n = 9-23 for knock-
downs). (b) Relative Ki67+ area of whole EBs, and CD31+ sheet areas, in knock-down EB clones. Statistical significance was determined by two-
tailed, unpaired, t-tests. Bars are means ± S.E.M (Emp, empty lentiviral construct; Scr1, Scr2, scrambled siRNA sequences; KD1-3, knock-down
siRNA sequences; n = 9-23 for whole EBs, n = 1-47 for CD31+ sheets; * p < 0.05, ** p < 0.01, † p < 0.005, †† p < 0.001).
Figure 7 Effect of Egfl7 knock-down on embryoid body sprouting angiogenesis. Day 7 and day 14 differentiated EBs were grown between
two layers of collagen type I gel for 11 days, before being subjected to indirect IF using an antibody against CD31, and Hoechst nuclear dye
(arrows, CD31+ cords; arrowheads, CD31+ sheets).
Durrans and Stuhlmann Journal of Angiogenesis Research 2010, 2:4
http://www.jangiogenesis.com/content/2/1/4
Page 10 of 12in part by the over-proliferation specifically of ECs dur-
ing vasculogenesis. The CD31+ sheets appear to be
abnormal endothelial structures lacking a complete
basement membrane and cell junctions, which after
further differentiation are accompanied by the formation
of extensive endothelial cord networks. This indicates
that partial remodelling occurs within the EBs, and
points to an early developmental role for Egfl7.T h u s ,
using an siRNA knock-down approach which did not
affect miR-126 levels, we show here for the first time
that Egfl7 has a role during endothelial cell differentia-
tion and vascular development in mammalian cells.
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